G. Caforio, A. Bertolino - Vol. 10, June 2004, Issue 2
Testo Bibliografia Summary Indice
La disregolazione dopaminergica nella Schizofrenia
Dopaminergic dysregulation in schizophrenia
1 Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia. Neuroscience 1991;41:1-24.
2 Grace AA. Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia. J Neural Transm 1993;91:111-34.
3 Garris PA, Walker QD, Wightman RM. Dopamine release and uptake rates both decrease in the partially denervated striatum in proportion to the loss of dopamine terminals. Brain Res 1997;753:225-34.
4 Murase S, Grenoff J, Chouvet G, Gonon FG, Svennson T. Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studied in vivo. Neurosci Letts 1993;157:53-6.
5 Garris PA, Wightman RM. Different kinetics govern dopaminergic transmission in the amygdala, prefrontal cortex, and striatum: an in vivo voltammetric study. J Neurosci 1994;14:442-50.
6 Robinson TE, Whishaw IQ. Normalization of extracellular dopamine in striatum following recovery of a partial unilateral 6-OHDA lesion of the substantia nigra: A microdialysis study in freely moving rats. Brain Res 1988;450:209224.
7 Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 1990;13:290-6.
8 Cheramy A, Barbeito L, Godeheu G, Desce JM, Pittaluga A, Galli T, et al. Respective contributions of neuronal activity and presynaptic mechanisms in the control of the in vivo release of dopamine. J Neural Transm 1990;29(Suppl):183-93.
9 Parsons LH, Justice JB Jr. Extracellular concentration and in vivo recovery of dopamine in the nucleus accumbens using microdialysis. J Neurochem 1992;58:212-8.
10 Grace AA. The depolarization block hypothesis of neuroleptic action: Implications for the etiology and treatment of schizophrenia. J Neural Transm 1992;36(Suppl):91-131.
11 Fabre M, Rolls ET, Ashton JP, Williams G. Activity of neurons in the ventral tegmental region of the behaving monkey. Behav Brain Res 1983;9:213-35.
12 Schultz W, Romo R. Dopamine neurons of the monkey midbrain: contingencies of responses to stimuli eliciting immediate behavioral reactions. J Neurophysiol 1990;63:607-24.
13 Glowinski J, Cheramy A, Romo R Barbeito L. Presynaptic regulation of dopaminergic transmission in the striatum. Cell Molec Neurobiol 1998;8:7-17.
14 Blaha CD, Yang CR, Floresco SB, Barr AM, Phillips AG. Stimulation of the ventral subiculum of the hippocampus evokes glutamate receptor-mediated changes in dopamine efflux in the rat nucleus accumbens. Eur J Neurosci 1997;9: 902-911.
15 Grace AA. Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Res Rev 2000;31:330-41.
16 Moghaddam B, Gruen R. Do endogenous excitatory amino acids influence striatal DA release? Brain Res 1991;544:329-30.
17 Verma A, Moghaddam B. Regulation of striatal dopamine release by metabotropic glutamate receptors. Synapse 1998;28:220-6.
18 Breier A, Adler CM, Weisenfeld N, Su TP, Elman I, Picken L, et al. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 1998;29:142-7.
19 Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 1997a; 154:805- 11.
20 Breier A, Su TP, Saunders R, Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997b;94:2569-74.
21 Laruelle M, D'Souza CD, Baldwin RM, Abi-Dargham A, Kanes SJ, Fingado CL, et al. Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 1997a;17:162-74.
22 Laruelle M, Iyer RN, al-Tikriti MS, Zea-Ponce Y, Malison R, Zoghbi SS, et al. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in non human primates. Synapse 1997;25:1-14.
23 O’Donnell P, Grace AA. Dysfunctions in multiple interrelated systems as the neurobiological bases of schizophrenic symptom clusters. Schizophr Bull 1998;24:267-83.
24 Barch DM, Carter CS. Selective attention in schizophrenia: Relationship to verbal working memory. Schizophr Res 1998;33:53-61.
25 Gold JM, Carpenter C, Randolph C, Goldberg TE, Weinberger DR. Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch Gen Psychiatry 1997;54:159-65.
26 Goldberg TE, Weinberger DR, Berman KF, Pliskin NH, Podd MH. Further evidence for dementia of the prefrontal type in schizophrenia? A controlled study of teaching the Wisconsin Card Sorting Test. Arch Gen Psychiatry 1987;44:1008-14.
27 Goldberg TE, Kelsoe JR, Weinberger DR, Pliskin NH, Kirwin PD, Berman KF. Performance of schizophrenic patients on putative neuropsychological tests of frontal lobefunction. Int J Neurosci 1988;42:51-8.
28 Goldberg TE, Weinberger DR. Probing prefrontal function in schizophrenia with neuropsychological paradigms. Schizophr Bull 1988;14:179-83.
29 Keefe RS, Roitman SE, Harvey PD, Blum CS, Du Pre RL, Prieto DM, et al. A pen-and paper human analogue of a monkey prefrontal cortex activation task: Spatial working memory in patients with schizophrenia. Schizophr Res 1995;17:25-33.
30 Mahurin RK, Velligan DI, Miller AL. Executive-frontal lobe cognitive dysfunction in schizophrenia: A symptom subtype analysis. Psychiatry Res 1998;79:139-49.
31 Park S, Holzman PS. Schizophrenics show spatial working memory deficits. Arch Gen Psychiatry 1992;49:975-82.
32 Stone M, Gabrieli JD, Stebbins GT, Sullivan EV. Working and strategic memory deficits in schizophrenia. Neuropsychology 1998;12:278-88.
33 Weickert TW, Goldberg TE, Gold JM, Bigelow LB, Egan MF, Weinberger DR. Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect. Arch Gen Psychiatry 2000;57:907-13.
34 Wexler BE, Stevens AA, Bowers AA, Sernyak MJ, Goldman-Rakic PS. Word and tone working memory deficits in schizophrenia. Arch Gen Psychiatry 1988;55:1093-6.
35 Andreasen NC, O’Leary DS, Cizadlo T, Arndt S, Rezai K, Ponto LL, et al. Schizophrenia and cognitive dysmetria: A positron-emission tomography study of dysfunctional prefrontal – thalamic-cerebellar circuitry. Proc Natl Acad Sci USA 1996;93:9985-90.
36 Andreasen NC, O’Leary DS, Flaum M, Nopoulos P, WatkinsGL, Boles Ponto LL, et al. Hypofrontality in schizophrenia: Distributed dysfunctional circuits in neuroleptic naive patients. Lancet 1997;349:1730-4.
37 Berman KF, Torrey EF, Daniel DG, Weinberger DR. Regional cerebral blood flow in monozygotic twins discordant and concordant for schizophrenia. Arch Gen Psychiatry 1992;49:927-34.
38 Callicott JH, Ramsey NF, Tallent K, Bertolino A, Knable MB, Coppola R, et al. Functional magnetic resonance imaging brain mapping in psychiatry: Methodological issues illustrated in a study of working memory in schizophrenia. Neuropsychopharmacology 1998;18:186-96.
39 Callicott JH, Bertolino A, Mattay VS, Langheim FJ, Duyn J, Coppola R, et al. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb Cortex 2000;10:1078-92.
40 Carter CS, Perlstein W, Ganguli R, Brar J, Mintun M, Cohen JD. Functional hypofrontality and working memory dysfunction in schizophrenia. Am J Psychiatry 1998;155:1285-7.
41 Kawasaki Y, Maeda Y, Suzuki M, Urata K, Higashima M, Kiba K, et al. SPECT analysis of regional cerebral blood flow changes in patients with schizophrenia during the Wisconsin Card Sorting Test. Schizophr Res 1993;10:109-16.
42 Manoach DS, Press DZ, Thangaraj V, Searl MM, Goff DC, Halpern E, et al. Schizophrenic subjects activate dorsolateral prefrontal cortex during a working memory task, as measured by fMRI. Biol Psychiatry 1999;45:1128-37.
43 Manoach DS, Gollub RL, Benson ES, Searl MM, Goff DC, Halpern E, et al. Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance. Biol Psychiatry 2000;48:99-109.
44 Stevens AA, Goldman-Rakic PS, Gore JC, Fulbright RK, Wexler BE. Cortical dysfunction in schizophrenia during auditory word and tone working memory demonstrated by functional magnetic resonance imaging. Arch Gen Psychiatry 1998;55:1097-103.
45 Volz HP, Gaser C, Hager F, Rzanny R, Mentzel HJ, Kreitschmann- Andermahr I, et al. Brain activation during cognitive stimulation with the Wisconsin Card Sorting Test: A functional MRI study on healthy volunteers and schizophrenics. Psychiatry Res 1997;75:145-57.
46 Weinberger DR, Berman KF, Zec RF. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia: I. regional cerebral blood flow evidence. Arch Gen Psychiatry 1986;43:114-24.
47 Weinberger DR, Berman KF, Illowsky BP. Phiysiological dysfunction of dorsolateral prefrontal cortex in schizophrenia III. A new cohort and evidence for a monoaminergic mechanism. Arch Gen Psychiatry 1988;45:609-15.
48 Weinberger DR, Berman KF, Suddath R, Torrey EF. Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: A magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. Am J Psychiatry 1992;149:890-7.
49 Abrams R, Taylor MA. Differential EEG patterns in affective disorder and schizophrenia. Arch Gen Psychiatry 1979;36:1355-8.
50 Guenther W, Davous P, Godet JL, Guillibert E, Breitling D, Rondot P. Bilateral brain dysfunction during motor activation in type II schizophrenia measured by EEG mapping. Biol Psychiatry 1988;23:295-311.
51 Hoffmann RE, Buchsbaum MS, Jensen RV, Guich SM, Tsai K, Nuechterlein KH. Dimensional complexity of EEG waveforms in neuroleptic-free schizophrenic patients and normal control subjects. J Neuropsychiatry Clin Neurosci 1996;8:436-41.
52 Karson CN, Coppola R, Morihisa JM, Weinberger DR. Computed electroencephalographic activity mapping in schizophrenia: The resting state reconsidered. Arch Gen Psychiatry 1987;44:514-7.
53 Tauscher J, Fischer P, Neumeister A, Rappelsberger P, Kasper S. Low frontal electroencephalographic coherence in neuroleptic-free schizophrenic patients. Biol Psychiatry 1998;44:438-47.
54 Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK, et al. Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 2001;50:825-44.
55 Baddeley A. Human memory. Theory and practice. Massachussets 1990.
56 Goldman-Rakic PS. The physiological approach: Functional architecture of working memory and disordered cognition in schizophrenia. Biol Psychiatry 1999;46:650-61.
57 Bertolino A, Esposito G, Callicott JH, Mattay VS, Van Horn JD, Frank JA, et al. Specific relationship between prefrontal neuronal N-acetylaspartate and activation of the working memory cortical network in schizophrenia. Am J Psychiatry 2000;157:26-33.
58 Berman I, Niegner B, Merson A, Pappas D, Green AI. Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia. Schiz Res 1997;25:1-10.
59 Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987;44:660-9.
60 Callicott JH, Bertolino A, Egan MF, Mattay VS, Langheim FJ, Weinberger DR. Selective relationship between prefrontal N-acetylaspartate measures and negative symptoms in schizophrenia. Am J Psychiatry 2000;157:1646-51.
61 Carr DB, Sesack SR. Projections from the rat prefrontal cortex to the ventral tegmental area: Target specificity in the synaptic associations with mesaccumbens and mesocortical neurons. J Neurosci 2000;20:3864-73.
62 Jackson ME, Frost AS, Moghaddam B. Stimulation of prefrontal cortex at physiologically relevant frequencies inhibits dopamine release in the nucleus accumbens. J Neurochem 2001;78:920-3.
63 Christie MJ, James LB, Beart PM. An excitant amino acid projection from the medial prefrontal cortex to the anterior part of nucleus accumbens in the rat. J Neurochem 1985;45:477-82.
64 Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL, et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 2000;48:627-40.
65 Sams-Dodd F, Lipska BK, Weinberger DR. Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood. Psychopharmacology 1997;132:303-10.
66 Moghaddam B, Aultman J, Weinberger DR, Lipska BK. Neonatal damage of the rat ventral hippocampus impairs acquisition of a working memory task. Soc Neurosci 1999;25:1891(Abstr).
67 Bertolino A, Saunders RC, Mattay VS, Bachevalier J, Frank JA, Weinberger DR. Altered development of prefrontal neurons in rhesus monkeys with neonatal mesial temporolimbic lesions: A proton magnetic resonance spectroscopic imaging study. Cereb Cortex 1997;7:740-8.
68 Lipska BK, Weinberger DR. To model a psychiatric disorder in animals: Schizophrenia as a reality test. Neuropsychopharmacology 2000;23:223-39.
69 Goto Y, O'Donnell P. Delayed mesolimbic system alteration in a developmental animal model of schizophrenia. J Neurosci 2002;22:9070-7.
70 O’Donnell P, Lewis BL, Weinberger DR, Lipska BK. Neonatal hippocampal damage alters electrophysiological properties of prefrontal cortical neurons in adult rats. Cereb Cortex 2002;12:975-82.
71 Deutch AY. Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinson's disease. J Neural Transm Gen Sect 1993;91:197-221.
72 Kolachana BS, Saunders RC, Weinberger DR. Augmentation of prefrontal cortical monoaminergic activity inhibits dopamine release in the caudate nucleus: an in vivo neurochemical assessment in the rhesus monkey. Neuroscience 1995;69:859-68.
73 Harden DG, King D, Finlay JM, Grace A. Depletion of dopamine in the prefrontal cortex decreases the basal electrophysiological activity of mesolimbic dopamine neurons. Brain Res 1998;794:96-102.
74 Bertolino A, Knable MB, Saunders RC, Callicott JH, Kolachana B, Mattay VS, et al. The relationship between dorsolateral prefrontal N-acetylaspartate measures and striatal dopamine activity in schizophrenia. Biol Psychiatry 1999;45:660-7.
75 Bertolino A, Breier A, Callicott JH, Adler C, Mattay VS, Shapiro M, et al. The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia. Neuropsychopharmacology 2000;22:125-32.
76 Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 2002;5:267-71.
77 Callicot JH, Mattay VS, Bertolino A, Finn K, Coppola R, Frank JA, et al. Physiological characteristics of capacity contraits in working memory as revealed by functional MRI. Cerb Cortex 1999;9:20-6.
78 Lidow MS, Williams GV, Goldman-Rakic PS. The cerebral cortex: a case for a common site of action of antipsychotics. Trends Pharmacol Sci 1998;19:136-40.
79 Seamans JK, Gorelova N, Durstewitz D, Yang CB. Bidirectional dopamine modulation of GABAergic inhibition in prefrontal cortical pyramidal neurons. J Neurosci 2001;21:3628-38.
80 Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RB, et al. Effect of COMT Val108/158Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 2001;98:6917-22.
81 Akil M, Kolachana BS, Rothmond DA, Hyde TM, Weinberger DR, Kleinman JE. Catechol-O-Methyltransferase genotype and dopamine regulation in the human brain. J Neurosci 2003;23:2008-13.
82 Kinon, BJ, Lieberman JA. Mechanisms of action of atypical antipsychotics drugs: a critical analysis. Psychopharmacology 1996;124:2-34.
83 Bertolino A, Caforio G, Blasi G, de Candia M, Latorre V, Petruzzella V, et al. Interaction of COMT Val108/158Met genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry in press.
84 Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999;21(Suppl 2):106S-115S.
85 Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry 2001;158:360-9.
86 Kuroki T, Meltzer HY, Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 1999;288:774-81.
87 Gessa GL, Devoto P, Diana M, Flore G, Melis M, Pistis M. Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex. Neuropsychopharmacology 2000;22:642-9.
88 Tamminga CA. Partial dopamine agonists in the treatment of psychosis. J Neural Transm 2002;109:411-20.
89 Kehr W, Carlsson A, Lindqvist M, Magnusson T, Atack C. Evidence for a receptor mediated feedback control of striatal tyrosine hydroxylase activity. J Pharm Pharmacol 1972;24:744-7.
90 Walters JR, Bunney BS, Roth RH. Piribedil and apomorphine: pre- and postsynaptic effects on dopamine synthesis and neuronal activity. Adv Neurol 1975;9:273-84.
91 Carlsson A. Receptor mediated control of dopamine metabolism. In: Usdin, ed. Pre- and postsynaptic receptors. New York: Marcel Dekker 1975, pp. 49-65.
92 Ariens EJ. Affinity and intrinsic activity in the theory of competitive inhibition. Arch Int Pharmacodyn Ther 1954;99:32-49.
93 Ariens EJ. Intrinsic activity: partial agonists and partial antagonists. J Cardiovasc Pharmacol 1983;5(Suppl 1):S8-15.
94 Kenakin TP. Pharmacologic analysis of drug-receptor interaction. New York: Raven Press, 1993.
95 Carlsson A. Dopamine receptor agonists: intrinsic activity vs. state of receptor. J Neural Transm 1983;57:309-15.
96 Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-36.
97 Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human D2 dopamine receptors. J Pharmacol Exp Ther 2002;302:381- 9.
98 Inoue T, Domae M, Yamada K, Furukawa T. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl] butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther 1996;277:137-43.
99 Carlsson A, Waters N, Waters S, Carlsson ML. Network interactions in schizophrenia-therapeutic implications. Brain Res Rev 2000;31:342-9.
100 Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics: Part 1. ‘‘Goldilocks’’ actions at dopamine receptors. J Clin Psychiatry 2001a;62:824-41.
101 Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics: Part 2. Illustrating their mechanism of action. J Clin Psychiatry 2001b;62:923-4.
102 Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002;441:137-40.
103 Glennon RA, Dukat M. Serotonin subtypes and their characteristics. In: Bloom FE, Kupfer, DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press 1995, pp. 415-29.
104 Leysen JE, Janssen PMF, Schotte A, Luyten WHML, Megens AAHP. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical role of 5-HT2 receptors. Psychopharmacology 1993;112:S40.
105 Rao ML, Möller HJ. Biochemical findings of negative symptoms in schizophrenia and their positive relevance to pharmacologic treatment. Neuropsychobiology 1994;30:160-4.
106 Kasper S, Tauscher J, Kufferle B, Barnas C, Pezawas L, Quiner S. Dopamine- and serotonin-receptors in schizophrenia: results of imaging studies and implications for pharmacotherapy in schizophrenia. Eur Arch Psychiatry Clin Neurosci 1999;249(Suppl 4):83-9.
107 Raheja RK, Bharwani I, Penetrante AE. Efficacy of risperidone for behavioral disorders in the elderly: a clinical observation. J Geriatr Psychiatry Neurol 1995;8:159-61.
108 Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 1999;60(Suppl 10):5-14.
109 Yeung PP, Carson WH, Saha AR, McQuade RD, Ali MW, Stringfellow JC, et al. Efficacy of aripiprazole, a novel antipsychotic, in schizophrenia and schizoaffective disorder: results of a placebo-controlled trial with risperidone. Eur Neuropsychopharmacol 2001;11(Suppl 3):S241.
110 Saha AR, Carson WH, Ali MW, Dunbar GC, Ingenito G. Efficacy and safety of aripiprazole and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. WJ Biol Psychiatry 2001;2(Suppl 1):305S.
111 Carson WH, McQuade RD, Ali M, Saha AR, Dunbar GC, Ingenito G. A double-blind, placebo-controlled trial of aripiprazole and haloperidol. Schizophr Res 2001;49(Suppl 1):221.
112 Cornblatt B, Kern RS, Carson WH, Stock E, Ali M, Ingenito G, et al. Neurocognitive effects of aripiprazole versus olanzapine in patients with stable psychosis. Schizophr Res 2002;53(Suppl 3):1-274.